Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06613035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Twice-per-weekSelinexor, 2 Days Melphalan

StatusNot Yet Recruiting
PhasePhase 3
Started2024-09-30
View on ClinicalTrials.gov ↗
Twice-per-week Selinexor, 2 days Melphalan plus BU2FLU3 compared with BU3FLU5 for elder high-risk acute myeloid leukemia undergoing allogenic hematopoietic cell transplantation: a multi-center randomized phase 3 trial
Trial Details
NCT Number NCT06613035
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Acute Myeloid Leukemia
Enrollment 126 participants
Start Date 2024-09-30
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-25